White House Crypto Advisor: CLARITY Act Could Meet About 90% of Industry Regulatory Needs
Svmuu News: White House Crypto Policy Advisor Patrick Witt stated that if the Clarity Act passes smoothly, it could provide approximately 90% of the regulatory framework and policy certainty needed by the crypto industry. The bill is seen as one of the most critical pieces of legislation in the current U.S. crypto regulatory system, expected to strike a significant balance between compliance, market structure, and industry development. (Cointelegraph)
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Liquidity Crunch in Cryptocurrency Mining: Causes and Analysis of the Current Situation in 2026
-
3
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
4
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
5
The analysis points out that Iran’s overlapping centers of power complicate efforts to end the war with the United States, and that the Revolutionary Guards possess significant operational autonomy.
-
6
Israeli West Bank Settler Tells BBC Attacks on Palestinians Are Justified as Revenge, Equating One Jewish Life to "10 Million" Palestinians
-
7
ETH2X-FLI-P: An Analysis of the 2x Leveraged Ethereum Index Token on Polygon
-
8
WASM: An In-Depth Look at WebAssembly Technology and a Guide to Trading Related Tokens ZKWASM and WASM AI
-
9
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
10
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
Markets Today
Recommended Reading








